FDA panel unanimously votes down Parkinson's drug

October 17, 2011 in Medications

A panel of federal medical specialists has unanimously voted that a drug for Parkinson's disease from Teva Pharmaceuticals has not been shown to slow progress of the debilitating neurological disease.

Teva's Azilect is already approved to treat symptoms of Parkinson's, which causes tremors, and loss of balance.

Teva has asked the to expand approval so that it can be prescribed to slow the underlying disease. Currently no treatments are approved for that use.

But the FDA's panel of outside experts voted 17-0 against recommending approval for that use, saying the company's clinical study results were not convincing.

©2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Related Stories
Relevant PhysicsForums posts
  • Potential Breakthrough in Seizure Control
    created6 hours ago
  • Popping/Cracked sternum.
    created11 hours ago
  • Which Mental Illness Encompasses This Problem?
    created11 hours ago
  • A question about drug tolerance
    createdMay 23, 2012
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Missouri opts for untested drug for executions

(AP) -- The same anesthetic that caused the overdose death of pop star Michael Jackson is now the drug of choice for executions in Missouri, causing a stir among critics who question how the state can guarantee ...

Medications created May 24, 2012 | popularity not rated yet | comments 4

Aspirin may prevent recurrence of deep vein blood clots

(HealthDay) -- After suffering a type of blood clot called a venous thromboembolism, patients usually take a blood-thinner such as warfarin (Coumadin). But aspirin may do just as well after a period of time, ...

Medications created May 23, 2012 | popularity not rated yet | comments 2 | with audio podcast

Patients may receive too much acetaminophen in hospital

(HealthDay) -- Roughly 2.5 percent of admitted hospital patients may receive more than the safe daily cumulative dose of the pain-reliever acetaminophen, best known as Tylenol, on at least one day, according ...

Medications created May 23, 2012 | popularity 1 / 5 (1) | comments 0

New quality standards limiting elemental impurities in medicines announced

As part of its ongoing efforts to help ensure the quality of medicines, the U.S. Pharmacopeial Convention (USP) has announced two new standards related to elemental impurities: General Chapters Elemental Impurities—Limits and ...

Medications created May 23, 2012 | popularity not rated yet | comments 0

Quality standards for heparin further strengthened

To help further secure a safe supply of the widely–used blood thinner heparin, a third round of revisions to quality standards for the drug has been advanced by the U.S. Pharmacopeial Convention (USP). USP's Expert Panel ...

Medications created May 23, 2012 | popularity not rated yet | comments 0


Family history of Alzheimer's affects functional connectivity

(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...

Travel to high altitudes tied to Crohn's, colitis flare-ups

(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...

Transvaginal mesh op restores pelvic organ prolapse at price

(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Inherited DNA change explains overactive leukemia gene

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.